BMS 986036

Drug Profile

BMS 986036

Alternative Names: ARX-618; BMS-986036; FGF-21 mimetic proteins - Ambrx/Merck; PEG-FGF21; Pegylated FGF21; Pegylated-fibroblast growth factor-21 - Ambrx/Bristol-Myers Squibb

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ambrx
  • Developer Bristol-Myers Squibb
  • Class Antihyperglycaemics; Fibroblast growth factors; Hepatoprotectants; Obesity therapies; Polyethylene glycols; Proteins
  • Mechanism of Action Fibroblast growth factor 21 agonists; Fibroblast growth factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Fibrosis; Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
  • Phase I Liver disorders

Most Recent Events

  • 03 Apr 2018 Bristol-Myers Squibb plans a phase II trial for Non-alcoholic Steatohepatitis and Liver-cirrhosis in the US (NCT03486912)
  • 03 Apr 2018 Bristol-Myers Squibb plans a phase II trial for Non-alcoholic Steatohepatitis in the US , (NCT03486899)
  • 14 Feb 2018 Phase-I clinical trials in Liver disorders (In volunteers) in USA (SC) (NCT03445208)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top